Halozyme Therapeutics, Inc. $HALO Shares Newly Acquired by Riverbridge Partners LLC

Riverbridge Partners LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 132,015 shares of the biopharmaceutical company’s stock, valued at approximately $14,574,000. Riverbridge Partners LLC owned approximately 0.12% of Halozyme Therapeutics at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Horizon Investment Services LLC bought a new position in Halozyme Therapeutics during the 2nd quarter valued at $2,254,000. WINTON GROUP Ltd increased its position in shares of Halozyme Therapeutics by 704.6% during the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after purchasing an additional 52,848 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $1,025,000. Great Lakes Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $2,821,000. Finally, Chase Investment Counsel Corp bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $2,035,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 0.1%

Halozyme Therapeutics stock opened at $102.98 on Wednesday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. The firm has a market cap of $11.74 billion, a price-to-earnings ratio of 26.20, a price-to-earnings-growth ratio of 0.39 and a beta of 0.92. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $134.00. The firm’s 50 day moving average price is $115.07 and its two-hundred day moving average price is $85.05.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. The company had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The company’s quarterly revenue was up 39.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.72 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Matthew Posard sold 18,996 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the sale, the director directly owned 58,839 shares of the company’s stock, valued at $6,339,313.86. The trade was a 24.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 124,226 shares of company stock worth $13,370,893 over the last 90 days. Insiders own 2.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HALO shares. Stifel Nicolaus set a $130.00 price objective on Halozyme Therapeutics in a report on Friday, October 16th. JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Morgan Stanley set a $109.00 price target on shares of Halozyme Therapeutics and gave the company a “reduce” rating in a report on Wednesday. Finally, Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $108.18.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.